Immunadd, Inc.

Founded in 2021, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation. We are developing next generation saponin adjuvants and using them as the basis for new combination adjuvants and adjuvanted vaccines. Our lead adjuvant, IA05, is a rationally designed analogue of the saponin adjuvant QS-21. IA05 elicits immune responses comparable to or better than QS-21 and is better tolerated and more stable. With IA05 as the foundation, ImmunAdd is designing adjuvant platforms able to deliver a specific immune response.